CCL

Összesen 7 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM038652
Első szerző:Alberth Márta (fogszakorvos)
Cím:Significance of oral Candida infections in children with cancer / Alberth M., Majoros L., Kovalecz G., Borbás E., Szegedi I., Márton I. J., Kiss C.
Dátum:2006
ISSN:1219-4956
Megjegyzések:Candidiasis is common in children with cancer, particularly during periods of severe immunosuppression and neutropenia. Our aim was to study the microbiological changes in the oral cavity of children with newly diagnosed cancer. The study group consisted of 30 consecutive children and adolescents, 16 with acute lymphoblastic leukemia and 14 with solid tumors. Oral cultures to detect fungi and bacteria were conducted for all patients before treatment, during and after neutropenic episodes. In 23 patients developing fever simultaneous throat, urine and blood sampling was carried out. No pathogens were found in the cultures taken before the outset (30 cultures) or after recovery from (30 cultures) the neutropenic episodes. In the 45 oral cultures taken during the neutropenic episodes 38 (84.4%) proved positive. Fungi were the most frequently isolated oral pathogens: 33/38 yeast and 6/38 bacterial infections were identified. There was no association between the underlying malignancy and the occurrence of the positive cultures. Of the 30 patients, all 23 (76.7%) who have developed moderate-to-severe neutropenia, developed oral fungal colonization or clinically obvious fungal infection at least on one occasion during the study. In addition to oral samples, fungi were identified in 9/23 pharyngeal swabs, 6/23 urine and 1/23 blood cultures. The initial fungal pathogen was exclusively (33/33) Candida albicans. In extended severe neutropenic states, C. albicans was replaced by non-albicans species (C. kefyr, C. lusitaniae, C. sake, C. tropicalis) in 5 patients between 4 to 6 days of the neutropenic episodes. Four of the nonalbicans Candida strains were resistant to azole-type antifungal agents. Neutropenic episodes of children with cancer are associated with an increased risk of developing oral and even systemic infections with C. albicans that can be replaced by azole-resistant nonalbicans strains in prolonged neutropenia contributing to morbidity of these patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Pathology and Oncology Research. - 12 : 4 (2006), p. 237-241. -
További szerzők:Majoros László (1966-) (szakorvos, klinikai mikrobiológus) Kovalecz Gabriella (1973-) (fogszakorvos) Borbás Emese Szegedi István (1969-) (hematológus, onkológus, nefrológus) Márton Ildikó (1954-) (fogszakorvos) Kiss Csongor (1956-) (hematológus, onkológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM049348
035-os BibID:(PMID)23955198 (Scopus)84896034980 (WOS)000329356600017
Első szerző:Bárdi Edit (csecsemő- és gyermekgyógyász)
Cím:Value of FDG-PET/CT Examinations in Different Cancers of Children, Focusing on Lymphomas / Edit Bárdi, Mónika Csóka, Ildikó Garai, István Szegedi, Judit Müller, Tamás Györke, Kornélia Kajáry, Karolina Nemes, Csongor Kiss, Gábor Kovács
Dátum:2014
ISSN:1219-4956 1532-2807
Megjegyzések:The aim of the study was to assess sensitivity and specificity of FDG-PET/CT in different forms of childhood cancer. We retrospectively evaluated the results dedicated of 162 FDG-PET/CT examinations of 86 children treated with: Hodgkin lymphoma (HL; n=31), non-Hodgkin lymphoma (NHL; n=30) and other high grade solid tumors (n=25). Patients were admitted and treated in two departments of pediatric hematology and oncology in Hungary. FDG-PET/CT was performed for staging (n=25) and for posttreatment evaluation (n=137). Imaging was performed in three FDG-PET/CT Laboratories, using dedicated PET/CT scanners. False positive results were defined as resolution or absence of disease progression over at least 1 year on FDG-PET/CT scans without any intervention. In some cases histopathological evaluation of suspicious lesions was performed. Fals negative results were defined as negative FDG-PET/CT results in case of active malignancy. Positive predictive values (PPV) and negative predictive values (NPV) were calculated. NPV was 100 %. The highest PPV was observed in high grade solid tumors (81 %), followed by HL (65 %) and NHL (61 %). There was a major difference of PPV in different histological types of HL (50 % in HL of mixed-cellularity subtype, 90 % in nodular sclerosing, and 100 % in lymphocyte-rich and lymphocyte depleted HL). We treated one patient with nodular lymphocyte predominant HL, who had 5 false positive FDG-PET/CT results. PPV of T- and B-lineage NHL were similar (60 % and 62 %, respectively). We observed an interesting difference of PPV in different stages of HL and NHL. In HL PPV was higher in early than in advanced disease forms: 66 % in stage II HL and 60 % in stage III HL, whereas there was an inverse relationship between PPV and disease stages in NHL 0 % in stage I and II patients, 67 % in stage III and 100 % in stage IV patients. PPV was lower in males (54 %) than in females (65 %). PPV were 64 % vs. 58 % in patients under vs. over 10 years of age. Negative FDG-PET/CT results during follow-up reliably predict the absence of malignancy. Positive FDG-PET/CT scan results in general have a low PPV. The relatively high PPV in patients with histologically proven high grade solid tumors, advanced stages of NHL and with nodular sclerosing, lymphocyte-rich and lymphocyte depleted subtypes of HL warrant a confirmation by biopsy, whereas the watch-and-wait approach can be used in other forms of childhood cancer patients with a positive FDG-PET/CT result in course of follow-up examinations.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
FDG-PET/CT
Megjelenés:Pathology Oncology Research. - 20 : 1 (2014), p. 139-143. -
További szerzők:Csóka Mónika Garai Ildikó (1966-) (radiológus) Szegedi István (1969-) (hematológus, onkológus, nefrológus) Müller Judit Györke Tamás Kajáry Kornélia Nemes Karolina Kiss Csongor (1956-) (hematológus, onkológus) Kovács Gábor (gyermekhaematológus Budapest)
Pályázati támogatás:TÁMOP-4.2.2.A-11/1/KONV-2012-0025
TÁMOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM069451
035-os BibID:(WOS)000427432400020 (Scopus)85019612221
Első szerző:Kárai Bettina (orvos)
Cím:Expression of Coagulation Factor XIII Subunit A Correlates with Outcome in Childhood Acute Lymphoblastic Leukemia / Bettina Kárai, Zsuzsanna Hevessy, Eszter Szánthó, László Csáthy, Anikó Ujfalusi, Katalin Gyurina, István Szegedi, János Kappelmayer, Csongor Kiss
Dátum:2018
ISSN:1219-4956 1532-2807
Megjegyzések:Abstract Previously we identified B-cell lineage leukemic lymphoblasts as a new expression site for subunit A of blood coagulation factor XIII (FXIII-A). On the basis of FXIII-A expression, various subgroups of B-cell precursor acute lymphoblasticleukemia (BCP-ALL) can be identified. Fifty-five children with BCP-ALL were included in the study. Bone marrow samples were obtained by aspiration and the presenceof FXIII-A was detected by flow cytometry. G-banding and fluorescent in situ hybridization was performed according to standard procedures. The 10-year event-free survival (EFS)and overall survival (OS) rate of FXIII-A-positive and FXIII-A-negative patients showed significant differences (EFS: 84% vs. 61%, respectively; p = 0.031; OS: 89% vs.61%; p = 0.008). Of all the parameters examined, there was correlation only between FXIII-A expression and ♭B-other' genetic subgroup. Further multivariate Cox regression analysis of FXIII-subtype and genetic group or ♭B-other' subgroup identified the FXIII-A negative characteristic as an independent factor associated with poor outcome in BCP-ALL. We found an excellent correlation between long-term survival and the FXIII-A-positive phenotype of BCP lymphoblasts at presentation. The results presented seem to be convincing enough to suggest a possible role for FXIII-A expression in the prognostic grouping of childhood BCP-ALL patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Precursor B-cell acute lymphoblastic leukemia
Immunophenotype
Factor XIII-A
B-other' ALL
Megjelenés:Pathology and Oncology Research. - 24 : 2 (2018), p. 345-352. -
További szerzők:Hevessy Zsuzsanna (1966-) (laboratóriumi szakorvos) Szánthó Eszter (laboratóriumi szakorvos jelölt) Csáthy László (1979-) (laboratóriumi szakorvos) Ujfalusi Anikó (1968-) (gyermekorvos, laboratóriumi szakorvos) Gyurina Katalin (1986-) (tudományos segédmunkatárs) Szegedi István (1969-) (hematológus, onkológus, nefrológus) Kappelmayer János (1960-) (laboratóriumi szakorvos) Kiss Csongor (1956-) (hematológus, onkológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM102344
035-os BibID:(cikkazonosító)1610171 (WOS)000814739700001 (Scopus)85132960654
Első szerző:Kertész Gabriella
Cím:Case Report : a Child With Hemophilia A Serves as Donor for Hematopoietic Stem Cell Transplantation to Cure His Brother's Severe Aplastic Anemia / Kertész Gabriella, Kállay Krisztián, Kassa Csaba, Zombori Marianna, Bodó Imre, Kiss Csongor, Szegedi István, Kriván Gergely
Dátum:2022
ISSN:1219-4956 1532-2807
Megjegyzések:The first-line treatment of severe aplastic anemia is allogeneic hematopoietic stem cell transplantation with a matched sibling donor. However, co-morbidities of the identical donor can make donation difficult. We present a transplantation where in parallel with the patient's conditioning treatment, the preparation of the donor with severe hemophilia A required a special management with perioperative factor VIII substitution. Donation was successful without complications, and 18 months after transplantation, the patient and his donor are well without any long-term sequelae. To our knowledge, this is the first reported succesfull transplantation with hemophilic child serving as a bone marrow donor. The procedure did not mean a significant risk to donor health, so donors with hemophilia should not be excluded from donation.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Pathology & Oncology Research. - 28 (2022), p. 1-5. -
További szerzők:Kállay Krisztián Kassa Csaba Zombori Marianna Bodó Imre Kiss Csongor (1956-) (hematológus, onkológus) Szegedi István (1969-) (hematológus, onkológus, nefrológus) Kriván Gergely
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM101209
035-os BibID:(cikkazonosító)1610261 (WOS)000784109200001 (Scopus)85128409153
Első szerző:Müller Judit
Cím:Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary / Müller Judit, Szűcs-Farkas Dóra, Szegedi István, Csóka Monika, Garami Miklós, Tiszlavicz Lilla Györgyi, Hauser Péter, Kriván Gergely, Csanádi Krisztina, Ottóffy Gábor, Nagy Béla, Kiss Csongor, Kovács Gábor
Dátum:2022
ISSN:1219-4956 1532-2807
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
SARS-CoV-2
COVID-19
pediatric malignancy
chemotherapy delay
SARS-CoV-2S antibodies
Megjelenés:Pathology & Oncology Research. - 28 (2022), p. 1-6. -
További szerzők:Szűcs-Farkas Dóra Szegedi István (1969-) (hematológus, onkológus, nefrológus) Csóka Mónika Garami Miklós Tiszlavicz Lilla Györgyi Hauser Péter Kriván Gergely Csanádi Krisztina Ottóffy Gábor Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos) Kiss Csongor (1956-) (hematológus, onkológus) Kovács Gábor (gyermekhaematológus Budapest)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM040284
Első szerző:Szegedi István (hematológus, onkológus, nefrológus)
Cím:Differential regulation of umbilical cord blood and leukemic B cells by interferon-alpha (IFN-[alfa]) : observations in cultured cells / Szegedi I., Kiss C., Karászi E., Vámosi G., Szöllősi J., Kovács P., Benkő I.
Dátum:2006
ISSN:1219-4956
Megjegyzések:The exact mechanism of the beneficial therapeutic action of interferon-a (IFN-alpha) in B-cell-lineage malignancies has not been adequately explained. Here we report on the differential effect of IFN-alpha2b on non-malignant B cells of umbilical cord blood and leukemic B-cell lines JY, BL-41 and BCBL-1. Leukemic cell proliferation was characterized by colony assay, whereas apoptosis was investigated by flow cytometry of propidium iodide-stained cells. The degree of differentiation was evaluated by measuring the expression level of Fcgamma receptor-II (FcgammaRII) labeled with anti-CD32-FITC monoclonal antibody using flow cytometry. IFN-alpha protected umbilical cord blood CD19-positive B lymphocytes from apoptotic cell death in vitro. IFN-alpha significantly decreased colony formation of all three cell lines, and in contrast to normal cells, induced apoptosis in JY and BL-41 and excessive necrosis in HHV-8 infected BCBL-1 cells. FcgammaRII was upregulated both in normal and in leukemic B cells as indicated by an increase both in the proportion of CD32-positive cells and the mean fluorescence intensity. From our results it seems that antiproliferative, apoptotic and differentiative effects of IFN-alpha are interrelated but distinct cellular events, which are differentially regulated in normal, leukemic and virus-infected cells of the B-cell lineage.
Tárgyszavak:Természettudományok Biológiai tudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Pathology & Oncology Research. - 12 : 3 (2006), p. 159-163. -
További szerzők:Kiss Csongor (1956-) (hematológus, onkológus) Karászi Éva Vámosi György (1967-) (biofizikus) Szöllősi János (1953-) (biofizikus) Kovács Péter (1939-) (farmakológus) Benkő Ilona (1954-) (orvos, farmakológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM005647
Első szerző:Szegedi István (hematológus, onkológus, nefrológus)
Cím:Bcl-2 antisense oligonucleotide inhibits the proliferation of childhood leukemia/lymphoma cells of the B-cell lineage / Szegedi I., Katona K., Horváth A., Molnár A., Aradi J., Kiss C.
Dátum:2008
Megjegyzések:An 18-mer phosphorothioate bcl-2 atisense oligonucleotide (ASO) inhibited colony formation of three B-cell leukemia/lymphoma cell lines in a dose dependent manner in the range of 0.125-0.5 ?mol/l. The srcambled cogener had no detectable effect. A decrease in BCL-2 protein and apoptotic DNA fragmentation was detected in the studied cell lines and primary blast cells of two children with acute lymphoblastic leukemia. Neither BCL-2 protein level, nor DNA integrity was affected by the scrambled control indicating the specific effect ASO. As far as we know, this is the first report on the effects of bcl-2 ASO on childhood leukemia/lymphoma cell samples.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
BCL-2
Antisense oligonucleotide
Childhood
Leukemia
Lymphoma
Megjelenés:Pathology and Oncology Research. - 14 : 3 (2008), p. 275-279. -
További szerzők:Katona Klára (1976-) Horváth András (1976-) (vegyész) Molnár Anna (1980-) (általános orvos) Aradi János (1942-) (biokémikus, vegyész) Kiss Csongor (1956-) (hematológus, onkológus)
Internet cím:DOI
elektronikus változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.